Difficulty: Medium
Average Score: 89%
Practice
All the following characteristics are shared by flumazenil and naloxone Except:
Correct answer
B
Rationale
In this pharmacology question, the correct answer is B) Given orally. Flumazenil and naloxone are both used as antidotes to reverse the effects of benzodiazepines and opioids, respectively. However, they differ in their routes of administration. Flumazenil is administered intravenously, while naloxone can be given orally, making option B the correct choice.
Option A states that both drugs have a shorter half-life than their respective agonists, which is true for both flumazenil and naloxone. Option C is also correct as both drugs are used in anesthesia to reverse the central nervous system depression caused by their agonists. Option D is incorrect as naloxone is specifically a respiratory stimulant in opioid toxicity, not benzodiazepine toxicity.
Understanding the differences in pharmacological properties, such as route of administration, mechanism of action, and indications for use, is crucial for healthcare professionals to effectively and safely administer medications. This knowledge ensures that the right antidote is given in the right situation, preventing potential adverse effects and improving patient outcomes.
Option A states that both drugs have a shorter half-life than their respective agonists, which is true for both flumazenil and naloxone. Option C is also correct as both drugs are used in anesthesia to reverse the central nervous system depression caused by their agonists. Option D is incorrect as naloxone is specifically a respiratory stimulant in opioid toxicity, not benzodiazepine toxicity.
Understanding the differences in pharmacological properties, such as route of administration, mechanism of action, and indications for use, is crucial for healthcare professionals to effectively and safely administer medications. This knowledge ensures that the right antidote is given in the right situation, preventing potential adverse effects and improving patient outcomes.